1
|
Ishiguro N, Takahashi E, Arakawa H, Saito A, Kitagawa F, Kondo M, Morinaga G, Takatani M, Takahashi R, Kudo T, Mae SI, Kadoguchi M, Higuchi D, Nakazono Y, Tamai I, Osafune K, Jimbo Y. Improvement of Protein Expression Profile in Three-Dimensional Renal Proximal Tubular Epithelial Cell Spheroids Selected Based on OAT1 Gene Expression: A Potential In Vitro Tool for Evaluating Human Renal Proximal Tubular Toxicity and Drug Disposition. Drug Metab Dispos 2023; 51:1177-1187. [PMID: 37385755 DOI: 10.1124/dmd.122.001171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Revised: 06/05/2023] [Accepted: 06/21/2023] [Indexed: 07/01/2023] Open
Abstract
The proximal tubule plays an important role in the kidney and is a major site of drug interaction and toxicity. Analysis of kidney toxicity via in vitro assays is challenging, because only a few assays that reflect functions of drug transporters in renal proximal tubular epithelial cells (RPTECs) are available. In this study, we aimed to develop a simple and reproducible method for culturing RPTECs by monitoring organic anion transporter 1 (OAT1) as a selection marker. Culturing RPTECs in spherical cellular aggregates increased OAT1 protein expression, which was low in the conventional two-dimensional (2D) culture, to a level similar to that in human renal cortices. By proteome analysis, it was revealed that the expression of representative two proximal tubule markers was maintained and 3D spheroid culture improved the protein expression of approximately 7% of the 139 transporter proteins detected, and the expression of 2.3% of the 4,800 proteins detected increased by approximately fivefold that in human renal cortices. Furthermore, the expression levels of approximately 4,800 proteins in three-dimensional (3D) RPTEC spheroids (for 12 days) were maintained for over 20 days. Cisplatin and adefovir exhibited transporter-dependent ATP decreases in 3D RPTEC spheroids. These results indicate that the 3D RPTEC spheroids developed by monitoring OAT1 gene expression are a simple and reproducible in vitro experimental system with improved gene and protein expressions compared with 2D RPTECs and were more similar to that in human kidney cortices. Therefore, it can potentially be used for evaluating human renal proximal tubular toxicity and drug disposition. SIGNIFICANCE STATEMENT: This study developed a simple and reproducible spheroidal culture method with acceptable throughput using commercially available RPTECs by monitoring OAT1 gene expression. RPTECs cultured using this new method showed improved mRNA/protein expression profiles to those in 2D RPTECs and were more similar to those of human kidney cortices. This study provides a potential in vitro proximal tubule system for pharmacokinetic and toxicological evaluations during drug development.
Collapse
Affiliation(s)
- Naoki Ishiguro
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Etsushi Takahashi
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Hiroshi Arakawa
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Asami Saito
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Fumihiko Kitagawa
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Masayuki Kondo
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Gaku Morinaga
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Masahito Takatani
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Ryo Takahashi
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Takashi Kudo
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Shin-Ichi Mae
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Moeno Kadoguchi
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Daichi Higuchi
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Yuya Nakazono
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Ikumi Tamai
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Kenji Osafune
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| | - Yoichi Jimbo
- Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Company, Ltd., Kobe, Japan (N.I., A.S., G.M., M.T., R.T., T.K.); R&D Department, Industrial Division, Nikkiso Company, Ltd., Kanazawa, Japan (E.T., F.K., Ma.K., Y.J.); Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (H.A., Mo.K., D.H., Y.N., I.T.); and Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (S.M., K.O.)
| |
Collapse
|
2
|
Nakashima S, Iwamoto T, Takanashi M, Ogawara KI, Maruyama M, Higaki K. Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats. Pharm Res 2022; 39:2163-2178. [PMID: 35799082 DOI: 10.1007/s11095-022-03325-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 06/24/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE Serotonin (5-HT) is important for gastrointestinal functions, but its role in drug absorption remains to be clarified. Therefore, the pharmacokinetics and oral absorption of cephalexin (CEX) were examined under 5-HT-excessive condition to understand the role of 5-HT. METHODS 5-HT-excessive rats were prepared by multiple intraperitoneal dosing of 5-HT and clorgyline, an inhibitor for 5-HT metabolism, and utilized to examine the pharmacokinetics, absorption behavior and the intestinal permeability for CEX. RESULTS Higher levels of 5-HT in brain, plasma and small intestines were recognized in 5-HT-excessive rats, where the oral bioavailability of CEX was significantly enhanced. The intestinal mucosal transport via passive diffusion of CEX was significantly increased, while its transport via PEPT1 was markedly decreased specifically in the jejunal segment, which was supported by the decrease in PEPT1 expression on brush border membrane (BBM) of intestinal epithelial cells. Since no change in antipyrine permeability and significant increase in FITC dextran-4 permeability were observed in 5-HT-excessive rats, the enhanced permeability for CEX would be attributed to the opening of tight junction, which was supported by the significant decrease in transmucosal electrical resistance. In 5-HT-excessive rats, furthermore, total body clearance of CEX tended to be larger and the decrease in PEPT2 expression on BBM in kidneys was suggested to be one of the reasons for it. CONCLUSIONS 5-HT-excessive condition enhanced the oral bioavailability of CEX in rats, which would be attributed to the enhanced permeability across the intestinal mucosa via passive diffusion through the paracellular route even though the transport via PEPT1 was decreased.
Collapse
Affiliation(s)
- Shun Nakashima
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.,Global CMC Regulatory Office, Regulatory Affairs Department, Otsuka Pharmaceutical Co. Ltd., 3-2-27 Otedori Chuo-ku, Osaka, 540-10021, Japan
| | - Takeharu Iwamoto
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.,Scientific Crime Laboratory, Kanagawa Prefectural Police Head Quarter, 155-1 Yamashita-cho, Naka-ku, Yokohama, Kanagawa, 231-0023, Japan
| | - Masashi Takanashi
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.,Central Hyogo Area, Hanshin Dispensing Pharmacy, I & H Co., Ltd., 1-18 Ohmasu-cho, Ashiya, Hyogo, 659-0066, Japan
| | - Ken-Ichi Ogawara
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.,Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1, Motoyamakita, Higashinada-ku, Kobe, Hyogo, 658-8558, Japan
| | - Masato Maruyama
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan
| | - Kazutaka Higaki
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.
| |
Collapse
|